PresentationPresentation Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma PDF (1.89 MB) Read MorePresentation Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma: Phase I STOMP Trial PDF (3.21 MB) Read MorePresentation Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib & anti-CD38 mAb Refractory MM: STORM Study PDF (1.15 MB) Read MorePresentation SAIL: Phase II Results of Ara-c and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE™) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML PDF (622.01 KB) Read MorePresentation A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia PDF (144.43 KB) Read MorePresentation Combination of Selinexor with High-Dose Cytarabine and Mitoxantrone for Remission Induction in Acute Myeloid Leukemia is Feasible and Tolerable – A Phase I Study PDF (2.33 MB) Read MorePresentation RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) – inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity PDF (1.44 MB) Read MorePresentation Results of a Phase 2 trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export (SINE) in 114 Patients with Gynaecological Cancers PDF (1.37 MB) Read MorePresentation A Phase 1B/2 Study of Selinexor in Combination with Backbone Therapies for Treatment of Relapsed/Refractory Multiple Myeloma PDF (1.10 MB) Read MorePresentation Phase I Trial of the Combination of Selinexor (SEL), Liposomal Doxorubicin (DOX) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM) PDF (1.32 MB) Read More Previous 1 … 3 4 5 6 7 … 15 Next